Maternal antiviral treatment safeguards infants from hepatitis B transmission in contingencies of delayed immunoprophylaxis
| Autor: | Lingyun Shao, Jie Wang, Hanyue Zhang, Guocui Zhang, Chao Qiu, Yang Li, Xin Wang, Miaoqu Zhang, Yonglan Pu, Qing Lu, Yiqi Yu, Yinhua Gong, Bin Xu, Wenhong Zhang, Li Li, Qi Ling, Qiran Zhang, Ting Gu, Lifeng Cao, Zhonghua Li |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Hepatitis B virus
Pediatrics medicine.medical_specialty Mother to child transmission Third trimester medicine.disease_cause Antiviral Agents 03 medical and health sciences 0302 clinical medicine Pregnancy medicine Clinical endpoint Humans Hepatitis B e Antigens Pregnancy Complications Infectious Antiviral treatment Child Hepatitis B Surface Antigens Hepatology Transmission (medicine) business.industry Infant Newborn Infant Biological product Hepatitis B medicine.disease Infectious Disease Transmission Vertical 030220 oncology & carcinogenesis DNA Viral Female 030211 gastroenterology & hepatology business |
| Zdroj: | Liver International. 40:2377-2384 |
| ISSN: | 1478-3231 1478-3223 |
| DOI: | 10.1111/liv.14479 |
| Popis: | BACKGROUND & AIMS Effectiveness of maternal antiviral prophylaxis in mother-to-child transmission of hepatitis B virus (HBV) has been extensively explored in studies where standard immunoprophylaxis is well secured to the newborns. This real-world study aims to test if maternal antiviral prophylaxis can safeguard the newborn when immunoprophylaxis administration was delayed or missed. METHODS Hepatitis B surface antigen-positive pregnant women were categorized into mothers with HBV DNA levels ≥2 × 105 IU/mL receiving nucleos(t)ide analogue during the third trimester; mothers with HBV DNA levels ≥2 × 105 IU/mL without antiviral treatment; and those with HBV DNA levels |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |